HBV - Update on the Guidelines and Controversies in Management

4.43 (7 votes)

Recorded On: 10/24/2018

This webinar focuses on reviewing the highlights of the revised AASLD Clinical Practice Guidelines for HBV infection in the first talk.  The second presentation addresses a key area of controversy, namely the role of antiviral therapy in patients during the immunotolerant phase of chronic HBV infection.

Marc G. Ghany (Moderator)

Dr. Ghany is an Investigator at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases, and at Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda. He is member the Physician Consortium for Practice Improvement for Hepatitis C, which is jointly sponsored by the American Medical Association and AASLD and serves on the hepatitis C Guidance panel which is jointly sponsored by the AASLD and Infectious Diseases Society of America. His work has been honored with the Regal Award for Excellence in Gastrointestinal and Liver Disease and with several NIDDK service awards including the Director’s Award. He received his M.B. and B.Ch. from the Royal College of Surgeon’s, Dublin, and Master of Health Sciences in Clinical Research, Duke University. He completed residency at the Hospital of Saint Raphael, New Haven, Connecticut, a fellowship in gastroenterology at Tulane University, New Orleans, and a clinical fellowship at the Liver Diseases Section, NIDDK. Dr. Ghany’s focus is on translational research to improve the care and treatment outcomes of patients with chronic viral hepatitis. 

 

Norah A. Terrault

Dr. Norah Terrault is the Professor of Medicine and the Director of the Viral Hepatitis Center at the University of California San Francisco. She is recognized nationally and internationally for her work related to viral hepatitis, especially in the setting of liver transplantation.  She has authored more than 290 original articles, reviews and book chapters on viral hepatitis, including the recent AASLD Hepatitis B Treatment Guidelines. She has served as associate editor for Hepatology, is current Associate Editor for Hepatology Communications and a member of the AASLD HCV Guidance Committee. She is an investigator on several NIH-funded clinical studies in hepatitis B and C, as well as NASH and is an investigator on several ongoing clinical trials of novel therapies for patients with chronic liver diseases.

 

 

Kosh Aggarwal

Dr. Kosh Agarwal is a Consultant Hepatologist and Transplant Physician at the Institute of Liver Studies, King’s College Hospital. Dr Agarwal is the Lead for the Kings Viral Hepatitis Service, the largest treatment centre for viral hepatitis in the UK. In 1991 Dr Agarwal graduated from Newcastle University and his postgraduate training was undertaken in Newcastle with the majority of his clinical and research training at the Regional Liver and Transplant Unit. Prior to his appointment at King’s, Dr Agarwal was a consultant and honorary senior lecturer at the Regional Liver and Transplant Unit in Newcastle. He also spent a year at the Division of Liver Diseases, Mount Sinai, New York, USA. Dr Agarwal is an investigator for several ongoing studies evaluating the safety and efficacy of various antiviral treatment regimens for chronic Hepatitis B and C. He is a member of the EASL, AASLD, BASL, & ILTS.

Key:

Complete
Failed
Available
Locked
HBV - Update on the Guidelines and Controversies in Management
Open to view video.
Open to view video.